Merck (MRK) announced that it had received approval in the United States for its Keytruda drug to treat front-line advanced kidney cancer patients. This provides patients with a new treatment option that may help treat their cancer more adequately. On top of that, it's another win for Merck as Keytruda continues to dominate in multiple front-line cancer cases. There are a lot of competitors that are also looking to get their hat into this arena, which depending upon future data could shift the landscape. However, Merck has done well with Keytruda building upon